Cell Therapy News Volume 21.39 | Nov 9 2020

May 12, 2022

CTN 21.39 | Nov 9 2020

Cell Therapy News by STEMCELL Technologies

Vol. 21.39 – 9 November, 2020

TOP STORY
Defining
the Teratoma as a Model for Multi-Lineage Human Development

Researchers showed that inter-teratoma cell type heterogeneity was comparable with organoid systems, and teratoma gut and brain cell types correspond well to similar fetal cell types.
[Cell]

Abstract Graphical Abstract

The StemSpan™ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.

PUBLICATIONSRanked by the impact factor of the journal

Inhibition
of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity

Scientists report that limiting glutamine metabolism in cancer cells bolstered the effectiveness of anti-programmed death ligand-1 antibody.
[Molecular Cell]

Abstract Graphical Abstract

Generation
and Biobanking of Patient-Derived Glioblastoma Organoids and Their Application in CAR T Cell Testing

Investigators describe detailed procedures for generating glioblastoma organoids from surgically resected patient tumor tissue using a chemically defined medium without cell dissociation.
[Nature Protocols]

Full Article

Tp63-Expressing
Adult Epithelial Stem Cells Cross Lineages Boundaries Revealing Latent Hairy Skin Competence

Scientists demonstrated that epithelial stem cells of non-skin origin that express the transcription factor Tp63, a master gene for the development of epidermis and its appendages, could respond to skin morphogenetic signals.
[Nature Communications]

Full Article

Persistent STAT5 Activation Reprograms the Epigenetic Landscape in CD4⁺
T Cells to Drive Polyfunctionality and Antitumor Immunity

Researchers report that persistent activation of signal transducer and activator of transcription 5 in tumor-specific CD4⁺ T cells drives the development of polyfunctional T cells.
[Science Immunology]

Abstract

IL-6 Trans-Signaling Promotes the Expansion and Anti-Tumor Activity of CAR T Cells

Hyper IL-6-expressing CAR T-cells exhibited enhanced proliferation and antitumor efficacy in vitro and in xenograft models.
[Leukemia]

Abstract

The
Novel Interplay between CD44 Standard Isoform and the Caspase-1/IL1B Pathway to Induce Hepatocellular Carcinoma Progression

Scientists observed that cluster differentiation 44 standard isoform (CD44s) was responsible for caspase-1/IL1B activation both in hepatocellular carcinoma (HCC) tissues and five HCC cell lines. In normoxia conditions, CD44s knockdown repressed the activation of caspase-1/IL1B via stimulating AMPK-mediated autophagy.
[Cell Death & Disease]

Full Article

Highly
Efficient and Safe Genome Editing by CRISPR-Cas12a Using CRISPR RNA with a Ribosyl-2′-O-Methylated Uridinylate-Rich 3′-Overhang in Mouse Zygotes

The authors introduced methoxyl modifications at C2 in riboses in the U-rich 3′-overhang of crRNA. When mixed with Cas12a effector proteins, the ribosyl-2′-O-methylated U-rich crRNA enabled improvement of dsDNA digestibility.
[Experimental and Molecular Medicine]

Full Article

Antigen-Specific
Immunotherapy Combined with a Regenerative Drug in the Treatment of Experimental Type 1 Diabetes

Researchers report that treatment with liraglutide did not prevent type 1 diabetes in the spontaneous non-obese diabetic mouse model, but it tended to reduce leukocytic islet infiltration.
[Scientific Reports]

Full Article

Connect with us via LiveChat to ask your scientific support questions

REVIEWS

CRISPR-Cas
Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids

The authors review CRISPR-Cas systems and their latest developments with an emphasis on application to human cells. They also discuss how different CRISPR-based strategies can be used to accomplish a particular genome engineering goal.
[Cell Stem Cell]

Abstract

INDUSTRY AND POLICY NEWS

XNK
Therapeutics Receives US Orphan Drug Status for NK Cell-Based Immunotherapy in Multiple Myeloma

XNK Therapeutics AB announced it has received Orphan Drug Designation from the FDA for its leading investigational drug candidate in the treatment of multiple myeloma.
[XNK Therapeutics AB]

Press Release

LIfT
BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumors In Vivo

LIfT BioSciences announced that their flagship cell therapy, N-LIfT, has demonstrated migration to the human pancreatic tumor site, successfully infiltrating the orthotopically grown tumor in nude mice.
[LIfT BioSciences]

Press Release

Intellia
Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Intellia Therapeutics, Inc. announced that the first patient has been treated with NTLA-2001, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR). Intellia’s global Phase I study is to evaluate NTLA-2001 for hereditary ATTR with polyneuropathy.
[Intellia Therapeutics, Inc.]

Press Release

Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. announced important updates related to the development plan for SRP-9001, the company’s investigational gene transfer therapy for the treatment of Duchenne muscular dystrophy.
[Sarepta Therapeutics, Inc.]

Press Release

FEATURED EVENT

TOP STORY
Defining
the Teratoma as a Model for Multi-Lineage Human Development

Inhibition
of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity

Generation
and Biobanking of Patient-Derived Glioblastoma Organoids and Their Application in CAR T Cell Testing

Tp63-Expressing
Adult Epithelial Stem Cells Cross Lineages Boundaries Revealing Latent Hairy Skin Competence

Persistent STAT5 Activation Reprograms the Epigenetic Landscape in CD4⁺
T Cells to Drive Polyfunctionality and Antitumor Immunity

IL-6 Trans-Signaling Promotes the Expansion and Anti-Tumor Activity of CAR T Cells

The
Novel Interplay between CD44 Standard Isoform and the Caspase-1/IL1B Pathway to Induce Hepatocellular Carcinoma Progression

Highly
Efficient and Safe Genome Editing by CRISPR-Cas12a Using CRISPR RNA with a Ribosyl-2′-O-Methylated Uridinylate-Rich 3′-Overhang in Mouse Zygotes

Antigen-Specific
Immunotherapy Combined with a Regenerative Drug in the Treatment of Experimental Type 1 Diabetes

CRISPR-Cas
Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids

XNK
Therapeutics Receives US Orphan Drug Status for NK Cell-Based Immunotherapy in Multiple Myeloma

LIfT
BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumors In Vivo

Intellia
Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

2021 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

> See All Events

Project
Research Scientist – CRISPR/CAS9 Genome Editing

PhD Student – Adoptive T Cell Therapy of Cancer

Process
Development Lead – Gene Transfer

Vice President – Oncology and Cell Therapy

Research
Fellow Position – Neural Cell Therapy

> See All Jobs